TITLE

Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy

AUTHOR(S)
Simó, Marta; Velasco, Roser; Graus, Francesc; Verger, Eugenia; Gil, Miguel; Pineda, Estela; Blasco, Jaume; Bruna, Jordi
PUB. DATE
July 2012
SOURCE
Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p451
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Epilepsy in glioblastoma multiforme (GBM) patients is common. Hematological toxicity is a potential side effect of antiepileptic drugs (AEDs) and a frequent limiting-dose effect of temozolomide (TMZ). The aim of the study was to investigate the impact of AEDs on thrombocytopenia in GBM patients treated with radiotherapy and TMZ. A cohort of 101 newly diagnosed GBM patients treated with radiotherapy and TMZ was reviewed. Clinical data, presence of seizures, AEDs use, platelet count, and accumulated TMZ dose were analyzed at each cycle. Thrombocytopenia was operationalized as a continuous platelet count and a dichotomic variable (cut-off <100.000/mm). This cut-off represents the threshold beyond which TMZ treatment is modified. A linear and a probit pooled cross-sectional regression analysis were used to study the impact of age, gender, AEDs, and accumulated TMZ on thrombocytopenia. Impact of AEDs on survival was also analyzed. Thirty-five patients (35%) presented seizures at onset and 18 (27%) during follow-up. Seven (13%) needed two or more AEDs for seizure control. Grade 3-4 thrombocytopenia was found in 8%. Decrease in platelet count was related to accumulated TMZ ( p < 0.001), age ( p < 0.001), and valproate ( p = 0.004). Platelet count <100.000/mm was only associated with accumulated TMZ ( p = 0.001). Recursive Partitioning Analysis prognostic class was the only variable with significant impact on survival. Valproate and age had an independent negative effect on total platelet count, although neither had an effect on critical thrombocytopenia (<100.000/mm). Therefore, the systematic withhold of valproate in GBM patients might not be justified. Nevertheless, this negative effect may be taken into account especially in elderly patients.
ACCESSION #
76350892

 

Related Articles

  • A phase I study of nelfinavir concurrent with temozolomide and radiotherapy in patients with glioblastoma multiforme. Alonso-Basanta, Michelle; Fang, Penny; Maity, Amit; Hahn, Stephen; Lustig, Robert; Dorsey, Jay // Journal of Neuro-Oncology;Jan2014, Vol. 116 Issue 2, p365 

    We conducted a phase I trial to examine the maximally tolerated dose (MTD) of the oral protease inhibitor nelfinavir (NFV) in combination with temozolomide and concurrent radiotherapy in patients with glioblastoma and to gather preliminary data for response. The study was conducted in patients...

  • Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme? Gallo, Chiara; Buonerba, Carlo; Lorenzo, Giuseppe; Romeo, Valeria; Placido, Sabino; Marinelli, Alfredo // Journal of Neuro-Oncology;Nov2010, Vol. 100 Issue 2, p311 

    Glioblastoma multiforme (GBM), the highest grade malignant glioma, is associated with a grim prognosis-median overall survival is in the range 12-15 months, despite optimum treatment. Surgery to the maximum possible extent, external beam radiotherapy, and systemic temozolomide chemotherapy are...

  • Differential Effects of MicroRNAs on Glioblastoma Growth and Migration. Jeansonne, Duane; Pacifici, Marco; Lassak, Adam; Reiss, Krzysztof; Russo, Giuseppe; Zabaleta, Jovanny; Peruzzi, Francesca // Genes;Mar2013, Vol. 4 Issue 1, p46 

    Glioblastoma multiforme is characterized by rapid proliferation, aggressive metastatic potential, and resistance to radio- and chemotherapy. The matricellular protein CYR61 regulates cellular proliferation and migration and is highly expressed in Glioblastomas. MicroRNAs are 22-nucleotides long...

  • Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy. McPherson, Christopher; Gerena-Lewis, Margie; Breneman, John; Warnick, Ronald // Journal of Neuro-Oncology;Jul2012, Vol. 108 Issue 3, p521 

    Previously we demonstrated median survival of 69 weeks after combination therapy of permanent, low-activity I-125 seeds and BCNU wafers for recurrent glioblastoma multiforme (GBM). We designed this prospective phase I trial to assess efficacy of this combination treatment for newly diagnosed...

  • Monitoring of Radiochemotherapy in Patients with Glioblastoma Using O-(2-[18F]Fluoroethyl)-L-Tyrosine Positron Emission Tomography: Is Dynamic Imaging Helpful? Piroth, Marc D.; Liebenstund, Sarah; Galldiks, Norbert; Stoffels, Gabriele; Shah, Nadim J.; Eble, Michael J.; Coenen, Heinz H.; Langen, Karl-Josef // Molecular Imaging;Sep2013, Vol. 12 Issue 6, p388 

    Monitoring of radiochemotherapy (RCX) in patients with glioblastoma is difficult because unspecific alterations in magnetic resonance imaging with contrast enhancement can mimic tumor progression. Changes in tumor to brain ratios (TBRs) in positron emission tomography (PET) using...

  • Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. Petrecca, Kevin; Guiot, Marie-Christine; Panet-Raymond, Valerie; Souhami, Luis // Journal of Neuro-Oncology;Jan2013, Vol. 111 Issue 1, p19 

    Glioblastomas (GBM) are highly motile cancers that invade through normal brain. In the absence of curative chemotherapy this invasion, beyond surgical and radiotherapy margins, to distant brain sites is thought to be an important cause of treatment failure. Paradoxically, studies analyzing...

  • Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme. Champ, Colin; Palmer, Joshua; Volek, Jeff; Werner-Wasik, Maria; Andrews, David; Evans, James; Glass, Jon; Kim, Lyndon; Shi, Wenyin // Journal of Neuro-Oncology;Mar2014, Vol. 117 Issue 1, p125 

    Retrospective data suggests that low serum glucose levels during the treatment of glioblastoma multiforme (GBM) may improve clinical outcomes. As such, many patients are implementing a ketogenic diet (KD) in order to decrease serum glucose flux while simultaneously elevating circulating ketones...

  • Pediatric glioblastoma multiforme: A singleinstitution experience. Ansari, Mansour; Nasrolahi, Hamid; Kani, Amir-Abbas; Mohammadianpanah, Mohammad; Ahmadloo, Niloofar; Omidvari, Shapour; Mosalaei, Ahmad // Indian Journal of Medical & Paediatric Oncology;Jul-Sep2012, Vol. 33 Issue 3, p155 

    Background: Glioblastoma multiforme (GBM) is the most common astrocytoma in adults and has a poor prognosis, with a median survival of about 12 months. But, it is rare in children. We report our experience on the pediatric population (20 years or younger) with GBM. Patients and Methods:...

  • Mouse models of glioblastoma: lessons learned and questions to be answered. Janbazian, Loury; Karamchandani, Jason; Das, Sunit // Journal of Neuro-Oncology;Jun2014, Vol. 118 Issue 1, p1 

    Glioblastoma is the most common primary brain tumour in adults. While many patients achieve disease remission following treatment with surgical resection, radiation therapy and chemotherapy, this remission is brief and invariably followed by tumour recurrence and progression. Recent work using...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics